Rheumatic immune-related adverse events from checkpoint inhibitor therapy: a case series
Immune checkpoint inhibitors (ICIs) targeting cytotoxic Tlymphocyte associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), and its ligand PD-L1 are established cancer immunotherapies for solid tumor and hematologic malignancies. These therapies are involved in immune-related adverse...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Verduci Editore
2021-08-01
|
| Series: | Beyond Rheumatology |
| Subjects: | |
| Online Access: | https://www.beyond-rheumatology.org/wp-content/uploads/sites/10/2022/05/br-3-2-65.pdf |
| _version_ | 1797831388612788224 |
|---|---|
| author | Antonella Laria Alfredomaria Lurati Laura Castelnovo Antonio Tamburello Paola Maria Faggioli Antonino Mazzone |
| author_facet | Antonella Laria Alfredomaria Lurati Laura Castelnovo Antonio Tamburello Paola Maria Faggioli Antonino Mazzone |
| author_sort | Antonella Laria |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) targeting cytotoxic Tlymphocyte associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), and its ligand PD-L1 are established cancer immunotherapies for solid tumor and hematologic malignancies. These therapies are involved in immune-related adverse events (irAE), both general and rheumatic ones. In general, immune- related adverse events (irAE) management includes drugholding, tapering doses of corticosteroids, and specific immunosuppression for clinically severe cases, such as infliximab or mycophenolate. |
| first_indexed | 2024-04-09T13:51:28Z |
| format | Article |
| id | doaj.art-469cba45e2254acba7a589482b5b95c8 |
| institution | Directory Open Access Journal |
| issn | 2612-5110 |
| language | English |
| last_indexed | 2024-04-09T13:51:28Z |
| publishDate | 2021-08-01 |
| publisher | Verduci Editore |
| record_format | Article |
| series | Beyond Rheumatology |
| spelling | doaj.art-469cba45e2254acba7a589482b5b95c82023-05-08T14:50:55ZengVerduci EditoreBeyond Rheumatology2612-51102021-08-01310.4081/br.2021.65292Rheumatic immune-related adverse events from checkpoint inhibitor therapy: a case seriesAntonella Laria0Alfredomaria Lurati1Laura Castelnovo2Antonio Tamburello3Paola Maria Faggioli4Antonino Mazzone5Fornaroli Hospital Magenta (MI), Rheumatology Unit, Fornaroli Hospital Magenta (MI), Rheumatology Unit, Civil Hospital, Internal Medicine Unit, Legnano (MI), Italy, Civil Hospital, Internal Medicine Unit, Legnano (MI), Italy, Civil Hospital, Internal Medicine Unit, Legnano (MI), Italy, Civil Hospital, Internal Medicine Unit, Legnano (MI), Italy, Immune checkpoint inhibitors (ICIs) targeting cytotoxic Tlymphocyte associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), and its ligand PD-L1 are established cancer immunotherapies for solid tumor and hematologic malignancies. These therapies are involved in immune-related adverse events (irAE), both general and rheumatic ones. In general, immune- related adverse events (irAE) management includes drugholding, tapering doses of corticosteroids, and specific immunosuppression for clinically severe cases, such as infliximab or mycophenolate.https://www.beyond-rheumatology.org/wp-content/uploads/sites/10/2022/05/br-3-2-65.pdfimmune checkpoint inhibitors (icis)rheumatic immunerelated adverse events (irae) |
| spellingShingle | Antonella Laria Alfredomaria Lurati Laura Castelnovo Antonio Tamburello Paola Maria Faggioli Antonino Mazzone Rheumatic immune-related adverse events from checkpoint inhibitor therapy: a case series Beyond Rheumatology immune checkpoint inhibitors (icis) rheumatic immunerelated adverse events (irae) |
| title | Rheumatic immune-related adverse events from checkpoint inhibitor therapy: a case series |
| title_full | Rheumatic immune-related adverse events from checkpoint inhibitor therapy: a case series |
| title_fullStr | Rheumatic immune-related adverse events from checkpoint inhibitor therapy: a case series |
| title_full_unstemmed | Rheumatic immune-related adverse events from checkpoint inhibitor therapy: a case series |
| title_short | Rheumatic immune-related adverse events from checkpoint inhibitor therapy: a case series |
| title_sort | rheumatic immune related adverse events from checkpoint inhibitor therapy a case series |
| topic | immune checkpoint inhibitors (icis) rheumatic immunerelated adverse events (irae) |
| url | https://www.beyond-rheumatology.org/wp-content/uploads/sites/10/2022/05/br-3-2-65.pdf |
| work_keys_str_mv | AT antonellalaria rheumaticimmunerelatedadverseeventsfromcheckpointinhibitortherapyacaseseries AT alfredomarialurati rheumaticimmunerelatedadverseeventsfromcheckpointinhibitortherapyacaseseries AT lauracastelnovo rheumaticimmunerelatedadverseeventsfromcheckpointinhibitortherapyacaseseries AT antoniotamburello rheumaticimmunerelatedadverseeventsfromcheckpointinhibitortherapyacaseseries AT paolamariafaggioli rheumaticimmunerelatedadverseeventsfromcheckpointinhibitortherapyacaseseries AT antoninomazzone rheumaticimmunerelatedadverseeventsfromcheckpointinhibitortherapyacaseseries |